Filtered By:
Condition: Thrombosis
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 508 results found since Jan 2013.

Expanding use of new oral anticoagulants.
This article compares the pharmacological properties of the NOACs with those of warfarin, describes the clinical trial data with the NOACs in the approved indications, outlines the unmet medical needs that the NOACs address, highlights the potential limitations of the NOACs, and provides guidance on the optimal use of the NOACs. PMID: 25374671 [PubMed]
Source: F1000 Medicine Reports - December 1, 2014 Category: Biomedical Science Tags: F1000Prime Rep Source Type: research

Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden
IntroductionIn clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of these drugs in clinical practise.Methods and resultsAll patients treated with new oral anticoagulants at Sk?ne University hospital and Halland County Hospital Halmstad between 2009 and September 2013 was identified in the Swedish national quality registry for atrial fibrillation and anticoagulation (AuriculA). Medical records were reviewed to identify thromboembolism and major bleeding and compared to a warfar...
Source: Thrombosis Journal - December 2, 2014 Category: Hematology Authors: Ashkan LabafMartin CarlwePeter Svensson Source Type: research

Ultrasound Guided Fine Needle Aspiration Biopsy of Thyroid Nodules in Patients taking Novel Oral Anticoagulants.
Conclusions: It has previously been established that patients on historical anticoagulant agents do not need to discontinue therapy prior to minor procedures such as needle aspirations or dental procedures. Therefore, in patients currently taking dabigatran, rivaroxaban, or apixaban, we conclude that is reasonable and safe to continue the novel oral anticoagulant agents prior to USGFNAB of thyroid nodules without major risk of bleeding. This conclusion is based not only on the fact that minor procedures are considered safe in patients on NOACs, but also because patients on historical anticoagulant agents do not need to dis...
Source: Thyroid : official journal of the American Thyroid Association - January 16, 2015 Category: Endocrinology Tags: Thyroid Source Type: research

Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study
ConclusionMore than 75% of patients were adherent >80% during the first year. Patients with higher morbidity, including patients with a higher risk of stroke or bleeding, exhibited better adherence. This improvement may be attributable to more regular contact with the health care system.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 1, 2015 Category: Hematology Authors: Anders Gorst‐Rasmussen, Flemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, Gregory Y.H. Lip, Deirdre A. Lane Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
CONCLUSION: More than 75% of patients were adherent >80% during the first year. Patients with higher morbidity, including patients with a higher risk of stroke or bleeding, exhibited better adherence. This improvement may be attributable to more regular contact with the health care system. This article is protected by copyright. All rights reserved. PMID: 25594442 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 16, 2015 Category: Hematology Authors: Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA Tags: J Thromb Haemost Source Type: research

Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man
Dabigatran is an oral direct inhibitor indicated for stroke prevention in patients with atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that laboratory test and dose adjustments are not necessary; nevertheless, circumstances of excessive anticoagulation, decreased kidney function, and instances of significant bleeding and thrombosis require laboratory assessment. In order to gather experience in the management of global [activated partial thromboplastin time (APTT) and thrombin time (TT) with extended endpoint] and specific [ecarin chromogenic assa...
Source: Blood Coagulation and Fibrinolysis - January 30, 2015 Category: Hematology Tags: Case Reports Source Type: research

Overview of the New Oral Anticoagulants: Opportunities and Challenges.
Abstract The non-vitamin K oral anticoagulants (NOACs) are replacing warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. All the 4 agents are licensed in the United States for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism and rivaroxaban and apixaban are approved for thromboprophylaxis after elective hip or knee arthroplasty. The NOACs are at least as effective as warfarin, but are not only more convenient to administer because they can be given in fixed doses without routin...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 19, 2015 Category: Cardiology Authors: Yeh CH, Hogg K, Weitz JI Tags: Arterioscler Thromb Vasc Biol Source Type: research

Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
Abstract Four new oral anticoagulants (NOAC), apixaban, rivaroxaban, edoxaban, and dabigatran, are now available in the USA; however, only apixaban and rivaroxaban are FDA approved for the prevention of venous thromboembolism following orthopedic surgery. Apixaban, rivaroxaban, and edoxaban’s anticoagulant activity can be measured using a chromogenic anti-factor Xa assay but there is no widely available means of measuring dabigatran blood levels. None of the NOAC has an antidote. Dabigatran is 80 % renally excreted, and patients with atrial fibrillation taking dabigatran for stroke prevention should stop the d...
Source: Current Rheumatology Reports - April 8, 2015 Category: Rheumatology Source Type: research

The new oral anticoagulants: clinical use and reversal agent development
Warfarin has been the centre of oral anticoagulant therapy for over 60 years. Recent development of new oral anticoagulants (NOACs) has provided a safe and effective alternative for stroke prevention in patients with atrial fibrillation and for prevention of venous thromboembolism. Determination of their use in acute coronary syndrome has been hampered by increases in bleeding events in most large trials, especially when used with antiplatelet therapy. NOACs have equal or superior efficacy and safety profiles compared to warfarin, fewer drug interactions; no dietary restrictions; predictable responses that eliminates moni...
Source: ISBT Science Series - April 13, 2015 Category: Hematology Authors: J. Costin, J. Ansell, S. Bakhru, B. Laulicht, S. Steiner Tags: Invited Review Source Type: research

Uninterrupted Dabigatran versus Warfarin in the Treatment of Intracardiac Thrombus in Patients with non-Valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice and increases the risk of thrombus in the left atrial appendage (LAA) which is strongly associated with an increased risk of ischemic stroke [1, 2]. Embolic strokes caused by AF are typically severe, more commonly disabling and fatal compared with strokes not associated with AF [1, 3]. Transesophageal echocardiography (TEE) is a sensitive method for intracardiac thrombus identification. When AF lasts for 2 days, atrial thrombi may take place in up to 14% patients on TEE examination; the prevalence of thrombus in AF patients varies from 10% ...
Source: International Journal of Cardiology - April 15, 2015 Category: Cardiology Authors: Li Hao, Jing-quan Zhong, Wei Zhang, Bing Rong, Fei Xie, Jun-tao Wang, Xin Yue, Zhao-tong Zheng, Qing Zhu, Yun Zhang Tags: Letter to the Editor Source Type: research

Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Conclusions .- The RapidTEG activated clotting time test and the kaolin test appear to be capable of detecting and monitoring NOACs. The ecarin test may be used to differentiate between Xa inhibitors and direct thrombin inhibitors. Therefore, TEG may be a valuable tool to investigate hemostasis and the effectiveness of reversal strategies for patients receiving NOACs. PMID: 25927150 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - May 1, 2015 Category: Laboratory Medicine Authors: Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA Tags: Arch Pathol Lab Med Source Type: research

Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
In conclusion, in RCTs of pharmacological VTE prophylaxis in patients undergoing THR or TKR, there was no difference in the incidence of post-operative AT among patients treated with NOACs, compared to those treated with enoxaparin. PMID: 25946985 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 7, 2015 Category: Hematology Authors: Squizzato A, Lussana F, Cattaneo M Tags: Thromb Haemost Source Type: research

Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol
Abstract Acute ischemic stroke (AIS) patients receiving non-vitamin-K antagonist oral anticoagulants (NOAC) are commonly excluded from thrombolytic therapy, as interpretation of coagulation tests remains unclear. We aimed to investigate the applicability of a novel institutional protocol for thrombolysis based on current expert recommendations and NOAC specific coagulation assessment. We included hospitalized AIS patients receiving NOAC for at least 24 h and consecutive AIS patients not receiving NOAC into a prospective study. We performed standard coagulation tests and specific tests for dabigatran, rivaroxaban ...
Source: Journal of Thrombosis and Thrombolysis - May 23, 2015 Category: Hematology Source Type: research

Novel oral anticoagulants in the treatment of cerebral venous thrombosis.
Authors: Feher G, Illes Z, Komoly S, Hargroves D Abstract Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with extremely diverse clinical features, predisposing factors, brain imaging findings, and outcome. Anticoagulation is the cornerstone of CVT management, however, it is not supported by high-quality evicence. Novel oral anticoagulants (NOACs) have been extensively studied in patients with deep vein thrombosis (DVT), pulmonary embolism (PE) and non-valvular atrial fibrillation (NVAF). The aim of our work to review the available evidence for NOACs in the treatment of CVT. Based on our literature ...
Source: International Angiology - June 3, 2015 Category: Cardiology Tags: Int Angiol Source Type: research

Antithrombotic options for atrial fibrillation in 2012.
Authors: Rude J, Quevedo K, Rodriguez de Armas L, Mukherjee D Abstract Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therap...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research